Pipeline

January 19, 2020
Company Drug/Device Medical Condition Status
Alucent Biomedical Natural Vascular Scaffolding technology peripheral artery disease phase 1 trial enrolling up to 15 patients across five U.S. research sites
Clover Biopharmaceuticals SCB-313 malignant pleural effusions phase 1 trial dosing first patient in China
Tmunity CART-TnMUC1-01 TnMUC1-positive advanced cancers phase 1 trial dosing first patient
Cellectis UCART123 relapsed/refractory acute myeloid leukemia (AML) phase 1 trial dosing first patient
BioTheryX BTX-A51 relapsed/refractory AML phase 1 initiation of patient dosing
Innovation Pharmaceuticals Brilacidin ulcerative colitis phase 1 dosing of first cohort of 3 patients
Retrotope RT001 Friedreich’s ataxia phase 2/3 trial dosing of first patient
Zymeworks ZW25 locally advanced and/or metastatic HER2-positive, HR-positive breast cancer phase 2 trial initiated, enrolling up to 76 patients in the U.S. and Canada
Hutchison China MediTech surufatinib advanced solid tumors phase 2 trial initiated in China
Akero Therapeutics AKR-001 non-alcoholic steatohepatitis ongoing phase 2a trial expanded to include patients with compensated cirrhosis
Tolero Pharmaceuticals Alvocidib AML phase 2 trial first patient dosed
Tyme Technologies SM-88 (racemetyrosine) high-risk sarcomas phase 2 trial first patient dosed
Neuroptika NRO-1 dry eye disease phase 2 trial first patient enrolled of 120 patients
ContraFect exebacase Staph aureus bacteremia phase 3 trial first patient dosed, 350 patients
Akcea Therapeutics

Ionis Pharmaceuticals		 AKCEA-TTR-LRx transthyretin-mediated amyloid cardiomyopathy phase 3 trial initiated
Abeona Therapeutics EB-101 recessive dystrophic epidermolysis bullosa phase 3 trial initiated, assessing up to 15 patients
Cerevel Therapeutics tavapadon Parkinson’s disease Phase 3 trial initiated, enrolling 1,200 patients
Novavax NanoFlu influenza in older adults Fast-Track designation granted by the FDA
Arena Pharmaceuticals APD418 decompensated heart failure Fast-Track designation granted by the FDA
Presage Biosciences CIVO Technology Platform cancer IND approved by the FDA
Lannett Company cocaine hydrochloride nasal solution local anesthetic NDA approved by the FDA
Novo Nordisk Ozempic (semaglutide) cardiovascular events in diabetes patients approved by the FDA for additional indication
Neurelis Valtoco (diazepam) nasal spray intermittent, stereotypic episodes of frequent seizure activity approved by the FDA

 

Upcoming Events

Featured Products

Featured Stories

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here